Paulette (300246.SZ) announced its 2023 annual results, changing profit to loss to 65.1851 million yuan
According to the Zhitong Finance App, Paulette (300246.SZ) released its 2023 annual report. The company's revenue was 1,194 billion yuan, an increase of 0.87% over the previous year. The net loss attributable to shareholders of the listed company was 65.1851 million yuan. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 81.5033 million yuan, an increase of 1149.80% over the previous year. The basic loss per share was $0.247.
Guangdong Biolight Meditech Co., Ltd. (SZSE:300246) Shares Fly 28% But Investors Aren't Buying For Growth
Those holding Guangdong Biolight Meditech Co., Ltd. (SZSE:300246) shares would be relieved that the share price has rebounded 28% in the last thirty days, but it needs to keep going to repair the rece
Paulette (300246.SZ) has been re-certified as a high-tech enterprise
Gelonghui, March 5 | Paulette (300246.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. The certificate number is GR202344006246. The issuance period is December 28, 2023, and is valid for three years.
Paulette (300246.SZ): Proposed internal transfer of subsidiary shares
Gelonghui, March 4, 丨 Paulette (300246.SZ) announced that the company held the 13th meeting of the 8th board of directors on March 4, 2024 to review and pass the “Proposal on Internal Transfer of Subsidiary Shares”. The board of directors agreed that in order to further optimize the company's management structure, improve business management and operation efficiency, and reduce management costs, the company plans to integrate subsidiaries related to the blood purification consumables business in Tianjin to develop medical devices owned by the wholly-owned subsidiary Tianjin Baolite Technology Co., Ltd. (hereinafter referred to as “Tianjin Medical Baolite”) Co., Ltd. (hereinafter referred to as “Day”
Paulette (300246.SZ) plans to increase Tianjin Baolite's capital by 8.657 million yuan through debt-for-equity swaps
Paulette (300246.SZ) announced that the company plans to use debt-for-equity swaps to Tianjin Baolite Medical Technology Co., Ltd...
Paulette (300246.SZ): A total cost of 6.9097 million yuan to buy back 1,01.05 million shares
Glonghui, March 4, 丨 Paulette (300246.SZ) announced that as of February 29, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 1,010.5 million shares, accounting for 0.3784% of the company's total share capital; the highest transaction price of the repurchase was RMB 7.02 yuan/share, the minimum transaction price was RMB 6.76 yuan/share, and the total transaction amount was RMB 690.097 million (excluding transaction fees such as stamp duty and transaction fees).
Paulette (300246.SZ): Initial repurchase of 25,600 shares involving 175.45 million yuan
Glonghui, Feb. 29 | Paulette (300246.SZ) announced that on February 28, 2024, the company repurchased the company's shares for the first time through a dedicated stock repurchase securities account. The number of repurchases was 25,600 shares, accounting for 0.0097% of the company's total share capital; the highest transaction price of the repurchase was RMB 6.88 yuan/share, and the minimum transaction price was RMB 6.84 yuan/share, and the total transaction amount was RMB 175.45 million (excluding transaction fees such as stamp duty and transaction fees).
Paulette (300246.SZ): Plans to spend 20 to 30 million yuan to buy back shares
Glonghui, Feb. 7 | Paulette (300246.SZ) announced that the company plans to repurchase shares for employee stock ownership plans or equity incentives. The total amount of capital to be used for the repurchase shall not be less than RMB 20.00 million (inclusive) and not more than RMB 30 million (inclusive). The price range to be repurchased does not exceed RMB 12 per share (inclusive). Based on the upper limit of the proposed repurchase price and the repurchase amount range, the number of repurchases was 1.666,700 to 2.5 million shares, accounting for 0.63% to 0.94% of the company's total share capital. This repurchase is actually used for employee stock ownership plans or equity incentives
The Market Doesn't Like What It Sees From Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Revenues Yet As Shares Tumble 26%
The Guangdong Biolight Meditech Co., Ltd. (SZSE:300246) share price has fared very poorly over the last month, falling by a substantial 26%. Instead of being rewarded, shareholders who have already
Baolite (300246.SZ) released results for the first three quarters, with net profit of 64.2788 million yuan, an increase of 529.58% over the previous year
Baolite (300246.SZ) released its report for the third quarter of 2023. The company achieved operating income of 9 in the first three quarters...
Baolite (300246.SZ): 889,700 owned shares will be listed and distributed on September 22
GLONGHUI September 20 | Paulette (300246.SZ) announced that the number of incentive recipients who met the vesting conditions is 107; the number of shares to be vested this time is 8897.17 million shares, accounting for 0.3374% of the company's current total share capital. The listing and circulation date of the shares currently owned is September 22, 2023 (Friday).
Paulette (300246.SZ): Controlling shareholders, actual controllers, directors, and senior managers promise not to reduce their holdings of the company's shares
GLONGHUI, September 14: Paulette (300246.SZ) announced that it has recently received a “Letter of Commitment on Not Reducing Company Shares” jointly issued by the company's controlling shareholder, actual controller, chairman and president, Mr. Yan Jinyuan, director and vice president, Mr. Liang Jin, director and vice president, Mr. Tang Wenpu, director of directors, Mr. Yang Yongxing, and financial director Ms. Xu Wei. The company's controlling shareholders, actual controllers, directors and senior managers who hold the company's shares have promised not to be within 6 months from September 14, 2023 Reduce your holdings in any way Company shares held; commitments
Baolite (300246.SZ) obtained 2 medical device registration certificates
Baolite (300246.SZ) announced that the company recently obtained 2 “Medical...” issued by the Guangdong Drug Administration
Paulette (300246.SZ): Net profit in the first half of the year increased 728.20% to 58.8587 million yuan
Gronhui (300246.SZ) released its 2023 semi-annual report. Revenue for the reporting period was 665 million yuan, up 19.22% year on year; net profit attributable to shareholders of listed companies was 588.587 million yuan, up 728.20% year on year; net profit attributable to shareholders of listed companies minus non-recurring profit and loss was 444.0.1 million yuan, up 1,072.95% year on year; basic earnings per share of 0.3091 yuan.
Paulette (300246.SZ): Obtained 2 medical device registration certificates
Glonway, July 21丨Paulette (300246.SZ) announced that the company recently obtained 2 “Medical Device Registration Certificates” issued by the Guangdong Drug Administration, which are infusion pumps and central monitoring software for infusion, respectively.
Paulette (300246.SZ): 10-04 - Blood purification and peritoneal dialysis equipment obtained medical device production license
According to the Zhitong Finance App, Paulette (300246.SZ) announced that the company's holding subsidiary, Sichuan Paulite Zhili Medical Technology Co., Ltd. (“Sichuan Paulite”), recently obtained a “Medical Device Production License” issued by the Sichuan Drug Administration. The production range is Class III: 10-04- blood purification and peritoneal dialysis devices. This time, Sichuan Paulite obtained the “Medical Device Production License”, indicating that the company's production base layout in the southwest region has basically been completed. Currently, the conditions for Sichuan Paulette to be put into operation are ready. With the subsequent launch of Sichuan Paulette and the expansion of production capacity, it will be beneficial to increase the public sector
Guangdong Biolight Meditech (SZSE:300246) Investors Are up 16% in the Past Week, but Earnings Have Declined Over the Last Three Years
By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with prowess, you can make superior returns. Just take a look at Guangdong Biolight Me
We Think That There Are More Issues For Guangdong Biolight Meditech (SZSE:300246) Than Just Sluggish Earnings
Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) stock rose after its recent weak earnings report. While shareholders may be willing to overlook soft profit numbers, we believe that they should
Medical Devices Maker Biolight Raises $83 Million From Share Placement
09:24 PM EST, 02/16/2022 (MT Newswires) -- Guangdong Biolight Meditech (SHE:300246) has raised 528 million yuan ($83.4 million) in net proceeds from the sale of shares in a private placement, accordi
The latest announcement of Paulette: net profit in 2021 is expected to decline by 77% and 83% compared with the same period last year.
Paulette announced that it is expected to make a profit of 60 million yuan to 78 million yuan in 2021, down 77.47% to 82.67% from the same period last year. Due to the impact of the epidemic, the company's revenue from health monitoring products in 2021 was significantly lower than that in 2020, and the sharp rise in the purchase price of chips in raw materials in 2021 led to a sharp increase in product costs. The chairman of the company is Yan Jinyuan. Mr. Yan Jinyuan: born in 1963, Chinese nationality, no permanent residence abroad, master's degree, senior engineer, associate professor, the products he presided over and designed have won the third prize of national invention of the State Science and Technology Commission and the second prize of scientific and technological progress of the State Education Commission.
No Data